Confo Therapeutics is the only GPCR company with a discovery engine that precisely targets desired GPCR conformations. This unique capability allows us to unlock a vast untapped potential for the discovery and development of breakthrough medicines. We are advancing a robust pipeline of large and small molecules focused on validated targets in endocrine and metabolic diseases, as well as addressing a broader array of critical unmet medical needs in collaboration with our partners. Our team of around 50 people is dedicated to advancing our technology, expanding our capabilities, and building out our pipeline in order to achieve the best possible therapeutic outcomes for patients
Confo Therapeutics is located on the Technology Park in Ghent. More information about Confo’s technology and strategy can be found on www.confotherapeutics.com.